As part of the agreement, Takeda paid Affymax upfront license fees of $122 million and purchased $10 million of equity. Takeda also committed to up to $355 million in clinical and development milestone payments across renal and oncology indications. In addition, Takeda funded the first $50 million of third party expenses related to clinical development of peginesatide. Subsequent to that, the agreement calls for Affymax to pay 30 percent and Takeda to pay the remaining 70 percent of all third-party peginesatide development expenses. Each company is responsible for their own overhead and personnel related expenses. Once the product is on the market, the companies will share profits equally in the United States and Takeda will pay Affymax royalties based on net sales of peginesatide outside the United States.
Affymax is pleased to have Takeda as its worldwide partner for peginesatide. Takeda is the largest pharmaceutical company in Japan and has a significant presence in the United States and Europe. ..
They need to spend to develop sales and marketing, so they will need some cash and it's either going to come from partner, dilution, or acquisition. What are the remaining milestones, don't care as much about past ones. Anyone know? Also, I did not listen to the cc did they disucc their US commercialization strategy, alone, partner?